Remission of paroxysmal atrial fibrillation with iron reduction in haemophilia A

Haemophilia

Volumn 16, Issue 5, 2010, Pages 726-730

  Zacharski, L R ^a   Mckernan, L ^a   Metzger, M E ^b   Malone, M G ^a   Samnotra, V ^a   Bhargava, A ^a   Steiner, P R ^a   Rauwerdink, C A ^a   Ornstein, D L ^a   Cornell, C J ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b Strafford Cardiology Associates   (United States)

Author keywords

Arrhythmia; Atherosclerosis; Clinical trial; Haemophilia; Iron

Indexed keywords

BLOOD CLOTTING FACTOR 8; DIGOXIN; FERRITIN; IRON; METOPROLOL; PROPAFENONE; SOTALOL; THYROTROPIN;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CASE REPORT; DIAPHORESIS; DIZZINESS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FERRITIN BLOOD LEVEL; GASTROESOPHAGEAL REFLUX; HEADACHE; HEART ATRIUM FIBRILLATION; HEART PALPITATION; HEMOCHROMATOSIS; HEMOPHILIA A; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERTENSION; INFORMED CONSENT; IRON BINDING CAPACITY; IRON BLOOD LEVEL; IRON DEFICIENCY; IRON OVERLOAD; IRON STORAGE; MALE; MUSCLE BLEEDING; OBESITY; PERONEUS NERVE PARALYSIS; PHLEBOTOMY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PSOAS MUSCLE; RADIOFREQUENCY ABLATION; REMISSION; SLEEP APNEA SYNDROME; SMOKING; THYROTROPIN BLOOD LEVEL; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT REFUSAL; WEAKNESS;

ATRIAL FIBRILLATION; FACTOR VIII; FERRITINS; HEMOPHILIA A; HUMANS; IRON OVERLOAD; MALE; MIDDLE AGED; PHLEBOTOMY; TREATMENT OUTCOME;

EID: 77955966907     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02218.x     Document Type: Article

References (44)

1. Medi C, Hankey GJ, Freedman SB. Atrial fibrillation. Med J Aust 2007, 186:197-202.
2. Ali S, Hong M, Antezano ES, Mangat I. Evaluation and management of atrial fibrillation. Cardiovasc Hematol Disord Drug Targets 2006, 6:233-44.
3. Steinberg JS, Sadaniantz A, Kron J. Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation 2004, 109:1973-80. Epub 2004 Mar 29
4. Oral H, Chugh A, Ozaydin M. Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation. Circulation 2006, 114:759-65. Epub 2006 Aug 14
5. Qureshi N, Avasarala K, Foote D, Vichinsky EP. Utility of holter electrocardiogram in iron-overloaded hemoglobinopathies. Ann N Y Acad Sci 2005, 1054:476-80.
6. Wu VC, Lin LY, Wu KD. QT interval dispersion in dialysis patients. Nephrology 2005, 10:109-12.
7. Wu VC, Huang JW, Wu MS. The effect of iron stores on corrected QT dispersion in patients undergoing peritoneal dialysis. Am J Kidney Dis 2004, 44:720-8.
8. Muhlestein JB. Cardiac abnormalities in hemochromatosis. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment 2000, 297-311. Barton JCEdwards CQ. In, eds, Cambridge, UK, Cambridge University Press, chapter 28
9. Vargas CA, Mendez HM, Rubio CE, Torres EA. Idiopathic hemochromatosis in a young man presenting with palpitations. Bol Asoc Med P R 1991, 83:19-21.
10. Hanson EH, Shue PM, Palm-Leis A, Rowley RK. An aviator with cardiomyopathy and genetic susceptibility to hereditary hemochromatosis: a case report. Aviat Space Environ Med 2001, 72:924-7.
11. Rosenqvist M, Hultcrantz R. Prevalence of a haemochromatosis among men with clinically significant bradyarrhythmias. Eur Heart J 1989, 10:473-8.
12. Woolf PK. A 19-year-old thalassemic with an irregular pulse. Pediatr Emerg Care 1993, 9:169-70.
13. Short EM, Winkle RA, Billingham ME. Myocardial involvement in idiopathic hemochromatosis. Morphologic and clinical improvement following venesection. Am J Med 1981, 70:1275-9.
14. Miskin H, Yaniv I, Berant M, Hershko C, Tamary H. Reversal of cardiac complications in thalassemia major by long-term intermittent daily intensive iron chelation. Eur J Haematol 2003, 70:398-403.
15. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol 1996, 95:26-36.
16. Borgna-Pignatti C, Rugolotto S, De Stefano P. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004, 89:1187-93.
17. Fabio G, Minonzio F, Delbini P, Bianchi A, Cappellini MD. Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH). Blood 2007, 109:362-4. Epub 2006 Sep 7
18. Zacharski LR, Ornstein DL, Woloshin S, Schwartz LM. The association of age, sex, and race with body iron stores in adults: analysis of NHANES III data. Am Heart J 2000, 40:98-104.
19. Zacharski LR, Chow B, Lavori PW. The Iron (Fe) and atherosclerosis study (FeAST). I. A pilot study of reduction of body iron stores in atherosclerotic peripheral vascular disease. VA Cooperative Study #410. Am Heart J 2000, 139:337-45.
20. Zacharski LR, Chow BK, Howes PS. Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease. JAMA 2007, 297:603-10.
21. Lekawanvijit S, Chattipakorn N. Iron overload thalassemic cardiomyopathy: iron status assessment and mechanisms of mechanical and electrical disturbance due to iron toxicity. Can J Cardiol 2009, 25:213-8.
22. Karahaliou A, Katsouras C, Koulouras V. Ventricular arrhythmias and antioxidative medication: experimental study. Hellenic J Cardiol 2008, 49:320-8.
23. Lipnitskii TN, Kozlovskii VA, Kutnyak VP. Experimental membrane-destructive model of cardiac arrhythmia. Bull Exp Biol Med 2003, 135:613-5.
24. Kuryshev YA, Brittenham GM, Fujioka H. Decreased sodium and increased transient outward potassium currents in iron-loaded cardiac myocytes. Implications for the arrhythmogenesis of human siderotic heart disease. Circulation 1999, 100:675-83.
25. Schwartz KA, Li Z, Schwartz DE, Cooper TG, Braselton WE. Earliest cardiac toxicity induced by iron overload selectively inhibits electrical conduction. J Appl Physiol 2002, 93:746-51.
26. Laurita KR, Chuck ET, Yang T. Optical mapping reveals conduction slowing and impulse block in iron-overload cardiomyopathy. J Lab Clin Med 2003, 142:83-9.
27. Glickstein H, El RB, Link G. Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood 2006, 108:3195-203. Epub 2006 Jul 11
28. Tanner MA, Galanello R, Dessi C. A randomized, placebo-controlled, double blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007, 115:1876-84. Epub 2007 Mar 19
29. Aessopos A, Kati M, Farmakis D, Polonifi E, Deftereos S, Tsironi M. Intensive chelation therapy in beta-thalassemia and possible adverse cardiac effects of desferrioxamine. Int J Hematol 2007, 86:212-5.
30. Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ. Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*. Hemoglobin 2006, 30:219-27.
31. Fleming DJ, Jacques PF, Tucker KL. Iron status of the free-living, elderly Framingham Heart Study cohort: an iron-replete population with a high prevalence of elevated iron stores. Am J Clin Nutr 2001, 73:638-46.
32. Fleming DJ, Tucker KL, Jacques PF. Dietary factors associated with the risk of high iron stores in the elderly Framingham Heart Study cohort. Am J Clin Nutr 2002, 76:1375-84.
33. Paraskevaidis IA, Iliodromitis EK, Vlahakos D. Deferoxamine infusion during coronary artery bypass grafting ameliorates lipid peroxidation and protects the myocardium against reperfusion injury: immediate and long-term significance. Eur Heart J 2005, 26:263-70. Epub 2004 Nov 30
34. Asirvatham SJ. Ablation for atrial fibrillation: can we decrease thromboembolism without increasing the risk for bleeding? Circulation 2007, 116:2517-9.
35. Mauser-Bunschoten EP, Fransen van de Putte DE, Schutgens RE. Co-morbidity in the ageing haemophilia patient: the down side of increased life expectancy. Haemophilia 2009, 15:853-63.
36. Siboni SM, Mannucci PM, Gringeri A. Health status and quality of life of elderly persons with severe haemophilia born before the advent of modern replacement therapy. J Thromb Haemost 2009, 7:780-6. for the Italian Association of Haemophilia Centres (AICE)
37. Dolan G, Hermans C, Klamroth R, Madhok R, Schutgens RE, Spengler U. Challenges and controversies in haemophilia care in adulthood. Haemophilia 2009, 15(Suppl. 1):20-7.
38. Tuinenburg A, Mauser-Bunschoten EP, Verhaar MC, Biesma DH, Schutgens RE. Cardiovascular disease in patients with hemophilia. J Thromb Haemost 2009, 7:247-54. Epub 2008 Oct 18
39. Ergelen M, Osmonov D, Gunaydi{dotless}n ZY, Sahin O, Isi{dotless}k T, Uyarel H. Acute inferior myocardial infarction in a patient with severe haemophilia A disease. Ann Hematol 2009, 88:711-2. Epub 2009 Jan 7
40. Marrocco-Trischitta MM, Melissano G, Castellano R, Coppi G, Chiesa R. Endovascular abdominal aortic aneurysm repair in a patient with severe hemophilia B. J Endovasc Ther 2009, 16:120-3.
41. Franchini M, Lippi G, Montagnana M. Hemophilia and cancer: a new challenge for hemophilia centers. Cancer Treat Rev 2009, 35:374-7. Epub 2009 Feb 4
42. Morris PJ. Physical activity recommendations for children and adolescents with chronic disease. Curr Sports Med Rep 2008, 7:353-8.
43. Zacharski LR, Chow BK, Howes PS. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst 2008, 100:996-1002.
44. Wood JC. History and current impact of cardiac magnetic resonance imaging on the management of iron overload. Circulation 2009, 120:1937-9.